Drug Profile
CDP 860
Alternative Names: anti-PDGF beta receptor antibody; anti-platelet derived growth factor beta receptor antibodyLatest Information Update: 30 Mar 2004
Price :
$50
*
At a glance
- Originator University of Washington; ZymoGenetics
- Developer Nektar Therapeutics
- Class Antineoplastics
- Mechanism of Action Intercellular signalling peptide and protein inhibitors; Platelet-derived growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Coronary artery restenosis
Most Recent Events
- 30 Mar 2004 Discontinued - Phase-II for Cancer in United Kingdom (unspecified route)
- 16 Jun 2003 CDP 860 is available for partnering (http://www.celltechgroup.com/)
- 29 Oct 2002 Inhale Therapeutic Systems and Celltech have entered into a licensing, manufacturing and supply agreement for CDP 860